Anand Mehra, MD
Anand joined Sofinnova Ventures in 2007 to focus on biopharmaceutical investing. Anand’s diverse background equips him to work with entrepreneurs on scientific, clinical, and strategic levels. Currently, he is a director of Aerie Pharmaceuticals (Nasdaq AERI), Marinus Pharmaceuticals and Prothena Corportaion (NASDAQ: PRTA) and led the firm\'s investment in Vicept Therapeutics (Acquired: Allergan). Anand served as a board member at NextWave Pharmaceuticals (Acquired: Pfizer) and also played an important role in the firm’s investments in Hyperion, Preglem (Acquired: Gedeon Richter), and Amarin (NASDAQ: AMRN).
Prior to joining Sofinnova Ventures, Anand worked in JP Morgan’s private equity and venture capital group, where he was heavily involved in new investments, management of their public portfolio, and the firm’s spin-out from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Company's pharmaceutical practice, advising pharma and biotech on key strategic issues, and an NIH-funded Fellow focused on reperfusion injury in stroke.
Anand received his M.D. from Columbia Medical School and graduated Phi Beta Kappa from the University of Virginia.
Assistant: Cassandra Fabel. Email: cassie(at)sofinnova.com.